Glenmark Share Price Target 2025, 2026, 2027 to 2030

Do you want to know the Glenmark share price target for the year 2025? Here, you will get a detailed analysis of the company’s financial performance, historical data, and price target for the year 2025, 2026, 2027, 2028, 2029, and 2030 provided by the market experts and analysts.

About Glenmark Limited

Glenmark is a company from India that makes medicine to help people feel better. It began many years ago and has its office in Mumbai. The company makes pills, creams, and other treatments for things like cough, skin rashes, and more. It also has smart teams that try to discover new medicines to treat hard diseases. The company’s goal is to help people stay healthy by making safe and useful medicines.

Glenmark Fundamentals

• Market Cap: ₹62,597.78 Cr.
• P/E Ratio: 38.87
• Book Value: ₹868.32
• Dividend Yield: 0.11 %
• ROE: 25.30 %
• ROCE: 32.59%
• 52-Week High: ₹2,286.15
• 52-Week Low: ₹1,274.70

Glenmark Shareholding Pattern

• Promoter: 46.65%
• FII: 23.16%
• DII: 1.74%
• Public: 15.59%
• Others: 12.86%

Glenmark Share Price Historical Data

Glenmark Share Price Target 2025 to 2030

Year Wise Analysis

Glenmark is a well known pharmaceutical company in India, and many experts believe it has strong potential for growth in the coming years. By 2025, its share price is expected to reach ₹2400. This growth could be driven by the company’s focus on developing new medicines and expanding its presence in international markets. If Glenmark continues to perform well, the share price may rise to ₹2780 in 2026.

As the company strengthens its research and launches more products, it could see the price touch ₹4100 by 2027. In 2028, the target is even higher at ₹4900, showing steady investor confidence. If global demand increases and the company keeps up its progress, the price could rise to ₹5650 in 2029. Looking at the long term, Glenmark’s share price might reach ₹6250 by 2030.

This steady climb reflects hopes for the company continued success in both domestic and global markets. For investors who are thinking about long-term opportunities, Glenmark may be a company worth watching. However, as with all stock investments, there is some risk, so it’s wise to research carefully and make decisions with the right knowledge.

Also Read: TCS Share Price Target 2025, 2026, 2027 to 2030

Glenmark Financials

In the financials section of Glenmark Pharmaceuticals Ltd, we will discuss its income statement and balance sheet, so you can decide whether this stock is good for you or not for trade.

Glenmark Income Statement

The company earned ₹3,268 crore this year, which is less than last year. But the good news is it still made a small profit of ₹4.65 crore, which is a big improvement compared to before. It spent ₹1,731 crore on business activities. Even though the profit was tiny, it’s better than losing money. Each share gave ₹7.21 to its owner. The company needs to work on increasing its income again, but it’s on the right track.

Glenmark Balance Sheet

The company owns things worth ₹16,050 crore. It has ₹1,705 crore in cash and short-term savings. After that, what’s left ₹8,849 crore belongs to the company owners. There are about 29 crore shares in the market. The company is financially stable and slowly improving, even though growth is happening step by step.

Glenmark Peer Companies

The peer companies of Glenmark Limited which are in tough competition areCipla, Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, Lupin, Aurobindo Pharma, Zydus Lifesciences, Torrent Pharmaceuticals, Alkem Laboratories, Cadila Pharmaceuticals, Wockhardt, Biocon, Natco Pharma.

F&Q

Rishi Gupta